AlphAIAlphAI — Financial news for AI agents
investing.comSEP 252 min read$CRSP

CRISPR Therapeutics stock analysis: pipeline catalysts vs. financial reality

CRISPR Therapeutics (CRSP) is trading at $54.71, down 1.78%. The company has generated revenue from its approved CRISPR medicine but remains in R&D stage with fluctuating financials. Revenue spiked in 2021 due to a milestone payment, but normalized in subsequent years. Analysts have mixed opinions, with some seeing significant upside and others valuing the stock lower. The company has a strong cash position and several upcoming clinical trial catalysts.

Original reporting
investing.com
Published Sep 25, 2026, 7:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 7:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CRSP
Neutral
medium confidence
Mentioned
$CRSP
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CRSPNeutralLow
01

Why it matters

The analysis underscores a valuation gap between model fair value and analyst targets, but no new data is disclosed.

02

Market read

The article is a secondary analysis of existing information; it offers limited actionable insight for traders.

03

What to watch

Potential regulatory or competitive developments in CRISPR space not covered in the article.

Relevance 4/10Novelty 2/10Timing: none

Background

CRISPR Therapeutics is the only company with an approved CRISPR therapy (CASGEVY) and is transitioning from R&D to commercial revenue.

Company-level read

Ticker impact

$CRSPNeutralMedium confidence
Context

The article provides a detailed analysis of CRISPR Therapeutics' financials, pipeline catalysts and valuation, making the stock a subject of trader interest.

Expected impact

Modest sideways movement; any reaction will depend on upcoming trial data releases.

Evidence & confidence

Analysis is based on previously disclosed financials and pipeline timelines; no fresh catalyst is reported.

Market effects

Sector

Reinforces cautious view on biotech sector cash‑burn dynamics.

Regional

Limited to US biotech investors.

Global

Low; no macro or cross‑sector effect.

Counterpoint

What could challenge this read

Despite cash runway, the high valuation relative to near‑zero revenue could justify a short bias.

Key entities

  • company
    CRISPR Therapeutics

    Biotech firm developing CRISPR‑based therapies.

Read at source← All news

Related articles

OCT 2
$CRSPMedAI 8/10

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

CRISPR Therapeutics (CRSP) will present Phase 1 clinical data on its gene-edited CAR T cell therapy, zugocabtagene geleucel (zugo-cel), for autoimmune diseases at the ACR Convergence 2026. The presentation focuses on the therapy's safety and efficacy in treating refractory systemic sclerosis. CRISPR Therapeutics is a biopharmaceutical company developing gene-based medicines, with a pipeline spanning various diseases.

globenewswire.com1 min
SEP 26
$SNOWMed

Snowflake, Palo Alto, Dell, GameStop, Crispr Insider Shock

Insiders at Snowflake (SNOW), Palo Alto (PANW), Dell (DELL), GameStop (GME), and Crispr (CRSP) made notable trades. SNOW's CRO sold $253,951 in shares, PANW's director sold $7.5M, DELL saw multiple sales totaling $22.9M, GME's CEO bought $26.4M in shares, and CRSP's shareholder sold $780,934. These transactions may signal insider expectations.

tipranks.com2 min
SEP 23
$CRSPMed

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.

newsable.asianetnews.com2 min
SEP 8
$CRSPMedAI 8/10

Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRISPR Therapeutics (CRSP) shares rose 19% in August following its Q2 earnings report. Sales of its blood disorder treatment Casgevy increased 78% to $76M, and the FDA expanded its approval. Revenue reached $10.2M, up from $892K a year ago, with a net loss of $91.5M. Analysts expected lower revenue and a larger loss. The company is developing treatments for hypertension and other disorders.

yahoo.com3 min
SEP 8
$CRSPMedAI 8/10

Where Will CRISPR Therapeutics Stock Be in 5 Years?

CRISPR Therapeutics (CRSP) reported $76M in Q2 2026 revenue from Casgevy, up 78% sequentially and 151% YoY. The company has a strong pipeline, including CTX310 for cardiovascular disease and Zugo-cel for autoimmune diseases. With $2.36B in cash and a $5.4B market cap, CRISPR has financial flexibility to advance multiple programs. Success in these areas could significantly increase its valuation by 2031, though risks remain.

yahoo.com3 min